Document text
Principal Investigator: Patrizia Farci
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2023
Award: $47,982
Funding agency: National Institute of Allergy and Infectious Diseases
1. Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
A. Generation and characterization of anti-SARS-CoV-2 mAbs using phage-display libraries from COVID-19 convalescent patients.
Peripheral blood samples were collected from 12 convalescent COVID-19 patients with high neutralizing serum antibody titers against SARS-CoV-2, and total RNA was extracted and used for the construction of four phage-display Fab libraries, derived from either a single donor or multiple donors combined. Three sequential cycles of panning were carried out to enrich for specific clones using a stabilized trimeric spike protein (S-2P) derived from the original SARS-CoV-2 strain, Wuhan-Hu-1. We obtained 18 Fabs that exhibited high-affinity binding to the viral spike with equilibrium dissociation constants (KD) in the picomolar or low nanomolar range.
B. Potent neutralization of diverse SARS-CoV-2 variants of concern.
The neutralizing activity of our 18 mAbs was evaluated using a pseudotype virus neutralization assay. Eleven showed potent neutralizing activity against the original SARS-CoV-2 strain (WA-1) and the Alpha variant, while 7 also neutralized the Delta variant in the picomolar range. In contrast, only 4 of the 11 mAbs were effective against the Beta variant. Of note, one of them, NA8, neutralized Beta, Omicron BA.1 and BA.2 sublineages with a picomolar potency, as well as BA.2.12.1 and BA.4 sublineages at nanomolar concentration. Since clinically approved mAbs are generally used in combination to ensure coverage against multiple variants, we compared side-by-side the neutralization potency of the combination of NA8 and NE12, used at equimolar concentrations (1:1), with that of 6 clinically approved antibodies used in paired combinations. Against the most recent variants, BA.2.12.1 and BA.4, the NA8/NE12 combination retained neutralizing activity at low nanomolar concentrations as did the REGN-10933/REGN-10987 combination, while COV2-2130/COV2-2196 was the most potent combination and LY-CoV555/LY-CoV016 was ineffective. These results suggest that NA8 and NE12, when used in combination, are one of the most broad and potent antibody pairs with picomolar or low nanomolar neutralizing activity against the major SARS-CoV-2 variants of concern. Based on these results, NA8 and NE12 were selected for further characterization and preclinical testing.
C. Structural analysis of antibodies NE12 and NA8.
To gain structural insight into the interactions of antibodies NE12 and NA8 with the SARS-CoV-2 spike glycoprotein, in collaboration with Peter Kwong and Yaroslav Tsybovsky, we obtained cryo-EM reconstructions of Fab NE12 and Fab NA8 bound to a stabilized spike trimer (S-6P) at nominal resolutions of 3.1 and 2.9 , respectively. The epitope of NE12 overlaps the ACE2 receptor footprint, indicating that NE12 directly blocks the spike-receptor interaction. Similar to Fab NE12, Fab NA8 shows extensive contacts with the receptor-binding ridge, but this antibody binds to a unique epitope along the outer side of the RBD distal from the tip. There is a moderate overlap between the NA8 epitope and the ACE2-binding interface of the RBD. These structural data further confirm that NE12 and NA8 provide a pair of potent complementary mAbs for potential clinical use.
D. Antibodies NE12 and NA8 protect hamsters from SARS-CoV-2 infection.
In collaboration with Ulla Buchholz, we tested the in vivo prophylactic efficacy of mAbs NE12 and NA8 in the golden Syrian hamster model, which closely mimics the severity of the disease in humans. Treatment with NA8 significantly protected hamsters from weight loss induced by two viral variants, WA-1 and Beta, while NE12 was highly effective against the WA-1 strain. Accordingly, the viral titers were significantly reduced in both the lungs and the nasal turbinates. Overall, these data demonstrate that mAb NA8 exerted strong prophylactic protection in vivo from two antigenically distinct SARS-CoV-2 variants, and NE12 exerted strong prophylactic protection against the original WA-1 strain in a highly susceptible animal model, despite the relatively low antibody doses used. In summary, these results show that broad and potent human antibodies can overcome the continuous immune escape of evolving SARS-CoV-2 variants.
E. Development of a universal neutralizing mAb against all SARS-CoV2 variants and other sarbecoviruses
The identification of potent, broadly neutralizing antibodies against SARS-CoV-2 variants of concern that resist neutralization by most mAbs, such as the B.1.351/Beta and the Omicron subvariants, is critical for creating an arsenal of therapeutic antibodies with high potency against both present and future variants of concern that will continue to emerge because of the sustained worldwide spread of this virus, leading to escape from current prophylactic and therapeutic interventions. Capitalizing on the data so far obtained, now we are focusing on the development of universal mAbs that are able to neutralize not only SARS-CoV-2 but also SARS-CoV-1 and other sarbecoviruses from other animal species such as bats. These antibodies are extremely important to prepare for potential new coronavirus-related pandemics caused by spill over from animals to humans.
2. Identification of Circulating Anti-PF4 Antibodies Associated with Disease Severity in Patients with COVID-19
The pathogenic mechanisms that trigger the most severe complications of COVID-19, which are often fatal, are still largely unknown. Severe COVID-19 is frequently associated with thrombosis and thrombocytopenia, which are reminiscent of the clinical presentation of two life-threatening syndromes: heparin-induced thrombocytopenia (HIT), which develops in patients treated with high doses of heparin after cardiac or orthopedic surgery, and vaccine-induced thrombosis with thrombocytopenia (VITT), which is a rare complication of adenovirus-vectored COVID-19 vaccines. The pathogenic mechanism of both the HIT and VITT syndromes involves the elicitation of autoantibodies that target partially cryptic epitopes in platelet factor 4 (PF4 or CXCL4), which are fully revealed upon binding to heparin or other polyanionic molecules. Using a clinically validated immunoassay, we evaluated the presence of antibodies to PF4 in 100 hospitalized patients with COVID-19 with moderate or severe disease, 25 acute COVID-19 cases visiting the Emergency Department and 65 convalescent individuals. Anti-PF4 antibodies were detected in 95 of 100 (95.0%) hospitalized COVID-19 patients irrespective of prior heparin treatment, while patients hospitalized for severe acute respiratory disease unrelated to COVID-19 had markedly lower levels. Higher antibody levels were detected in males than in females, and in African Americans and Hispanics than in White Caucasians (Liu Q, et al. 2022). Anti-PF4 antibody levels were correlated with the maximum disease severity score and with significant reductions in circulating platelet counts during hospitalization. In convalescent individuals from COVID-19, the antibody levels returned to near-normal values. Sera from COVID-19 patients induced higher levels of platelet activation than sera from healthy blood donors, but the results were not correlated with the levels of anti-PF4 antibodies. These results demonstrate that the vast majority of patients with severe COVID-19 develop anti-PF4 antibodies, which may play a role in the clinical complications of COVID-19, and have implications for the therapeutic management of the most severe cases.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Acute><Ad vector><Adenoviral Vector><Adenovirus Vector><Affinity><African American group><African American individual><African American people><African American population><African Americans><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antibody titer measurement><Antigenic Determinants><Antiheparin Factor><Assay><Autoantibodies><B.1.351><B.1.617.2><BA.1 variant><Bats><Binding><Binding Determinants><Bioassay><Biologic Assays><Biological Assay><Blood Platelet Count><Blood Platelet Factor IV><Blood Platelet Number><Blood Sample><Blood Serum><Blood donor><Blood platelet factor 4><Blood specimen><Body Weight decreased><COVID complications><COVID crisis><COVID epidemic><COVID infected patient><COVID pandemic><COVID patient><COVID positive patient><COVID related complications><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 complications><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related complications><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID19><COVID19 S protein><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cardiac Surgery><Cardiac Surgery procedures><Cardiac Surgical Procedures><Caucasian><Caucasian Race><Caucasians><Caucasoid><Caucasoid Race><Chemokine (C-X-C motif) Ligand 4><Chiroptera><Clinical><Clinical Treatment Moab><CoV emergence><CoV-2><CoV2><Collaborations><Complication><Conchae Nasales><Cricetinae><Cryo-electron Microscopy><Cryoelectron Microscopy><Data><Delta variant><Developing Countries><Developing Nations><Development><Disease><Disorder><Dissociation><Distal><Dose><ED visit><ER visit><Economics><Effectiveness><Electron Cryomicroscopy><Emergency care visit><Emergency department visit><Emergency hospital visit><Emergency room visit><Ensure><Epitopes><Equilibrium><Evolution><Exhibits><Factor 4><Female><Future><Generations><Genetic Alteration><Genetic Change><Genetic Diversity><Genetic Variation><Genetic defect><Goals><Golden Hamsters><Golden Syrian Hamsters><Hamsters><Hamsters Mammals><Heart Surgical Procedures><Heparin><Heparin Neutralizing Protein><Heparinic Acid><Hispanic Populations><Hispanic group><Hispanic individual><Hispanic people><Hispanics><Hospital Admission><Hospitalization><Human><Immune><Immune Evasion><Immunes><Immunoassay><Individual><Less-Developed Countries><Less-Developed Nations><Libraries><Life><Lung><Lung Respiratory System><Mesocricetus auratus><Modeling><Modern Man><Molecular Interaction><Monoclonal Antibodies><Mutation><Nasal><Nasal Passages Nose><Nasal turbinate bone structure><Non-Polyadenylated RNA><Normal Range><Normal Values><Nose><Occidental><Omicron BA.1><Orthopedic Surgery><PF4 Gene><Pathogenicity><Patients><Phage Display><Platelet Activation><Platelet Count><Platelet Count measurement><Platelet Factor 4><Platelet Number><Preclinical Testing><Predisposition><Prevention><Proteins><RNA><RNA Gene Products><RNA Viruses><Receptor Protein><Recombinant Platelet Factor 4><Resolution><Respiratory Disease><Respiratory System Disease><Respiratory System Disorder><Respiratory System, Nose, Nasal Passages><Ribonucleic Acid><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 B.1.351><SARS-CoV-2 B.1.617.2><SARS-CoV-2 BA.1><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 beta><SARS-CoV-2 delta><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 positive patient><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SCYB4><Sarbecovirus><Serum><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Severity of illness><Side><Small Inducible Cytokine B4><Small Inducible Cytokine Subfamily B, Member 4><South Africa strain><South Africa variant><South African strain><South African variant><Susceptibility><Syndrome><Syrian Hamsters><Technology><Therapeutic><Therapeutic Intervention><Therapeutic antibodies><Third-World Countries><Third-World Nations><Thrombocytopenia><Thrombopenia><Thrombosis><Turbinates><Under-Developed Countries><Under-Developed Nations><Vaccination><Vaccines><Variant><Variation><Viral><Virus><Weight Loss><Weight Reduction><Wuhan coronavirus><adeno vector><adenovector><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody titering><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><autoimmune antibody><autoreactive antibody><balance><balance function><body weight loss><combinatorial><complications due to COVID-19><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><corona virus disease 2019 vaccine><corona virus emergence><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease positive patient><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus emergence><coronavirus infectious disease-19><coronavirus patient><cryo-EM><cryoEM><cryogenic electron microscopy><developing country><developing nation><developmental><disease severity><economic><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experience><fighting><gamma-Thromboglobulin><genome mutation><global health><hCoV19><heart surgery><heparin-induced thrombocytopenia><immune evasive><in vivo><in vivo evaluation><in vivo testing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><intervention therapy><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><mAbs><male><model of animal><monoclonal Abs><nCoV><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><nano-molar><nanomolar><neutralizing antibody><neutralizing mAb><neutralizing monoclonal antibodies><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><peripheral blood><platelet factor IV><pre-clinical testing><prophylactic><pulmonary><receptor><receptor binding><receptor bound><reconstruction><resolutions><self reactive antibody><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 B.1.351><severe acute respiratory syndrome coronavirus 2 B.1.617.2><severe acute respiratory syndrome coronavirus 2 BA.1><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe acute respiratory syndrome-CoV><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><social><therapeutic vaccine><thrombotic disease><thrombotic disorder><treatment vaccines><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><vaccine for the treatment><vaccine for treatment><variants of concern><white race><wt-loss>